Fmr LLC Boosts Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

FMR LLC raised its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 178.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,412,380 shares of the company's stock after acquiring an additional 4,750,936 shares during the period. FMR LLC owned approximately 7.35% of Day One Biopharmaceuticals worth $103,254,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. GSA Capital Partners LLP bought a new stake in Day One Biopharmaceuticals during the third quarter valued at approximately $825,000. First Turn Management LLC bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter worth $13,204,000. Algert Global LLC increased its stake in Day One Biopharmaceuticals by 248.8% in the third quarter. Algert Global LLC now owns 71,487 shares of the company's stock valued at $996,000 after acquiring an additional 50,990 shares during the last quarter. TimesSquare Capital Management LLC raised its position in Day One Biopharmaceuticals by 8.2% during the third quarter. TimesSquare Capital Management LLC now owns 1,827,695 shares of the company's stock valued at $25,460,000 after purchasing an additional 139,160 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in shares of Day One Biopharmaceuticals by 517.0% in the 2nd quarter. AQR Capital Management LLC now owns 113,020 shares of the company's stock worth $1,557,000 after purchasing an additional 94,703 shares in the last quarter. Institutional investors own 87.95% of the company's stock.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $16.10, for a total transaction of $161,000.00. Following the completion of the transaction, the insider now owns 1,057,535 shares of the company's stock, valued at approximately $17,026,313.50. This trade represents a 0.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 51,745 shares of company stock worth $775,867 over the last three months. Company insiders own 8.40% of the company's stock.

Day One Biopharmaceuticals Price Performance

NASDAQ:DAWN traded down $0.34 during mid-day trading on Thursday, reaching $13.46. 881,481 shares of the company's stock traded hands, compared to its average volume of 962,174. The company has a 50 day moving average price of $14.29 and a 200-day moving average price of $14.09. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -13.07 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 12-month low of $11.51 and a 12-month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.58. The business had revenue of $93.76 million for the quarter, compared to the consensus estimate of $15.05 million. During the same quarter in the prior year, the company earned ($0.54) EPS. As a group, analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on DAWN shares. Needham & Company LLC restated a "buy" rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. TD Cowen upgraded shares of Day One Biopharmaceuticals to a "strong-buy" rating in a research report on Monday, November 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $35.71.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.